. 2022 Jan 30;269(7):3420–3429. doi: 10.1007/s00415-022-10979-2

Table 5.

Summary of safety outcomes reported by the four included trials

Study ID	Arm	Adverse events
Study ID	Arm	Respiratory depression, n (%)	Mortality, n (%)
[15]	IV lorazepam (n = 66)	7/66 (10.6%)	5/65 (7.7%)
	IV diazepam (n = 68)	6/68 (8.8%)	3/67(4.5%)
	IV placebo (n = 71)	11/71 (15.5%)	11/70 (15.7%)
[21]	IV levetiracetam + clonazepam (n = 68)	7/68 (10.3%)^a	3/66 (4.5%)^b
[21]	IV placebo + clonazepam (n = 68)	3/66 (4.5%)^a	4/65 (6.2%)^b
[23]	IV phenobarbital + phenytoin (n = 18)	NR	NR
[23]	IV diazepam + phenytoin (n = 18)	NR	NR
[22]	IM midazolam (n = 514)^c	33/514 (6.4%)	11/391 (2.8%)
[22]	IV lorazepam (n = 509)^c	51/509 (10%)	8/391 (2.0%)

IM intramuscular; IV intravenous; NR not reported

^ap = 0.33

^bp = 0.72

^cTotal enrolments